『Beta Finch - Pharma & Biotech - EN』のカバーアート

Beta Finch - Pharma & Biotech - EN

Beta Finch - Pharma & Biotech - EN

著者： Beta Finch
無料で聴く

【Amazonプライム会員限定】今ならプレミアムプランが4か月 月額99円。

10月19日まで。※適用条件あり
Leading pharmaceutical and biotechnology companies. AI-powered earnings call analysis for Pharma & Biotech (PHARMA). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.2026 Beta Finch 個人ファイナンス 経済学
エピソード
  • Johnson & Johnson Q3 2026 Earnings Analysis

    Johnson & Johnson Q3 2026 Earnings Analysis
    2026/10/15
    More earnings analysis: https://betafinch.com
    Groups: PHARMA (https://betafinch.com/groups/PHARMA), INCOME (https://betafinch.com/groups/INCOME)
    ──────────
    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, joined as always by Jordan, and today we're diving into Johnson & Johnson's third quarter 2026 results, reported Tuesday. Before we get going, a quick note — this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: And there's a lot to unpack here, Alex, because on the surface this looks like a messy quarter, but underneath it's actually a pretty strong one.

    ALEX: Right, let's start with the headline numbers. J&J posted $25.4 billion in revenue for Q3, up 6% operationally, which actually beat analyst expectations. Management raised full-year guidance and now expects full-year operational sales growth of 6.7% to 7.1%, putting them on track to cross $100 billion in annual revenue for the very first time in the company's 140-year history.

    JORDAN: That's a huge milestone. But here's where it gets messy — GAAP net earnings were just $210 million, and diluted EPS came in at nine cents, compared to $2.12 a year ago. That's a massive drop.

    ALEX: And the reason is a one-time hit, not a business problem. J&J took a $5.5 billion charge tied to resolving the ovarian talc litigation, plus costs from two acquisitions — Firefly Bio in oncology and a collaboration with Cell BioMedicine in cell therapy. Strip those out, and adjusted EPS was $2.59, down about 7.5% year-over-year, but mostly because of those deal-related expenses, not underlying weakness.

    JORDAN: Exactly. The core business is actually accelerating. Innovative Medicine — that's their pharma segment — grew 7.9% operationally to $16.8 billion, with eight brands growing double digits. Oncology alone grew 17%.

    ALEX: Let's talk about the stars of the show. Tremfya, their immunology drug, grew 68% in the quarter. CARVYKTI, their multiple myeloma cell therapy, up 35%. And RYBREVANT, for lung cancer, up 64%. Tom Cavanaugh, the head of Innovative Medicine, specifically called out Icotrokinra — their new oral psoriasis treatment — saying it's tracking better than almost any launch they've seen in psoriatic disease, with over 20,000 patients started in just months.

    JORDAN: What stood out to me is they're calling this a path to double-digit growth by 2030, and when an analyst from Goldman pressed CFO Joe Wolk on whether that assumes big acquisitions, he was pretty direct — no, it's organic. That's a meaningful claim given how reliant a lot of pharma growth stories are on M&A.

    ALEX: Now, MedTech is the other side of the story, and it's where things got rockier. That division only grew 2.5%, missing expectations. Management was candid about it — Timothy Schmid, who runs MedTech, basically said "our performance is below the standard we set internally."

    JORDAN: Two specific problem areas: international markets, especially due to disruption from the Middle East conflict affecting hospital purchasing and tender timing, and Abiomed, their heart pump business, which actually declined 1.5% because of a disputed study on high-risk PCI procedures. Execs pushed back hard on that study's methodology.

    ALEX: But it wasn't all bad news in MedTech. Shockwave, their cardiovascular device business, grew 17%. And they got FDA clearance for Ottava, their new surgical robot — first commercial customer already signed. That's a big long-term bet on competing with Intuitive Surgical in robotics.

    JORDAN: One housekeeping item investors should note — J&J confirmed they're still on track to spin off their orthopedics business, DePuy Synthes, by mid-2027, and they're leaning toward a straight spin-off rather than a sale.

    ALEX: Let's hit a couple of Q&A highlights. On Icotrokinra,

    This episode includes AI-generated content.
    続きを読む 一部表示
    7 分
  • Zoetis Q2 2026 Earnings Analysis

    Zoetis Q2 2026 Earnings Analysis
    2026/08/29
    More earnings analysis: https://betafinch.com
    Groups: PHARMA (https://betafinch.com/groups/PHARMA)
    ──────────
    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown, where we take the numbers and the noise from corporate earnings calls and turn them into something you can actually digest. I'm Alex.

    JORDAN: And I'm Jordan. Today we're diving into Zoetis, ticker ZTS, the animal health giant. Q2 2026 results, and Alex, this one's a bit of a bumpy ride.

    ALEX: It really is. But before we get into it — quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: Good to have that out front. So let's set the scene. Zoetis reported second quarter revenue of $2.5 billion — flat on a reported basis, actually down 1% organically. Adjusted net income came in at $781 million, down 2% organically. And here's the headline: they cut full-year guidance.

    ALEX: Yeah, this wasn't a small tweak either. New revenue guidance is $9.12 to $9.32 billion, which works out to a decline of 3% to 1% for the year. Adjusted net income guidance dropped to a range implying a decline of 9% to 5%. That's a meaningful reset.

    JORDAN: So what happened? Basically, the U.S. Companion Animal business — think dogs and cats, not cattle and chickens — got hit hard. Revenue there was down 11% in the U.S. Fewer vet visits, pet owners being more price-conscious, and a lot more competitors piling into categories Zoetis basically invented, like dermatology treatments.

    ALEX: Right, and that's the key tension here. Their blockbuster drug Apoquel and the whole Key Dermatology franchise — U.S. dermatology revenue was down 18% in the quarter. New competitors are using aggressive discounting and rebates to steal share, and it's not growing the overall market, it's just splitting up a shrinking pie.

    JORDAN: Even so, Zoetis still holds about 86% in-clinic share in U.S. dermatology, even after losing 10 points year-over-year. So they're still dominant, just under real pressure for the first time in a while.

    ALEX: And parasiticides — flea, tick, heartworm meds like Simparica — were basically flat globally, with the U.S. side down 6%. Management said it's less about a specific competitor and more about a broader pullback in vet visits.

    JORDAN: But here's the plot twist — it's not all bad news. Livestock had a phenomenal quarter, up 11% globally, and 23% in the U.S., partly boosted by demand for cattle parasiticides tied to that New World screwworm outbreak. And Diagnostics grew 12%, driven by point-of-care testing demand.

    ALEX: So basically, the pet side is struggling, but the farm animal side and the diagnostics side are picking up a lot of the slack.

    JORDAN: Exactly — that diversification is doing real work for them right now.

    ALEX: Let's talk strategy, because CEO Kristin Peck was pretty clear about their playbook. Instead of cutting list prices — which she called a "permanent structural change" — they're doing what's called gross-to-net investment. Basically targeted rebates, promotions, and bundling deals to protect market share without blowing up their pricing structure long-term.

    JORDAN: It's a defend-the-fort strategy. Protect volume and share now, keep the sticker price intact, and hope the competitive intensity eases once the market sorts itself out. CFO Wetteny Joseph said full-year price realization could land anywhere from flat to down 2%, depending on how aggressive they need to get.

    ALEX: There's also a leadership shakeup worth mentioning. Wetteny Joseph, the CFO, is stepping down after five years — a new hire, Jay Saccaro, is coming in not just as CFO but in a newly created combined CFO and Chief Operating Officer role, overseeing manufacturing and supply chain too. That's a pretty significant restructuring of the C-suite, aimed at s

    This episode includes AI-generated content.
    続きを読む 一部表示
    8 分
  • Vertex Pharmaceuticals Q2 2026 Earnings Analysis

    Vertex Pharmaceuticals Q2 2026 Earnings Analysis
    2026/08/29
    More earnings analysis: https://betafinch.com
    Groups: PHARMA (https://betafinch.com/groups/PHARMA)
    ──────────
    ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown! Today we're diving into Vertex Pharmaceuticals' second quarter 2026 results — and there's a lot going on: strong numbers, a major acquisition, and pipeline news across four disease areas. Before we get into it, quick disclaimer: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    JORDAN: Alright, Alex, let's start with the headline numbers because they're pretty solid.

    ALEX: Yeah, Vertex posted $3.3 billion in total revenue for Q2, up 12% year-over-year. That's driven largely by the cystic fibrosis franchise, which grew 11%, but also some real acceleration from the newer products.

    JORDAN: Right, and this is the part I find genuinely interesting — CASGEVY, their gene therapy for sickle cell disease and beta thalassemia, brought in $76 million this quarter. That's roughly 75% sequential growth and over 150% year-over-year. They had more infusions in the first half of 2026 than in all of 2025 combined.

    ALEX: That's a huge inflection point. And it's not slowing down either — they had over 100 patient initiations for a third straight quarter, plus a pediatric approval for ages two to eleven that came through in just 53 days post-filing.

    JORDAN: Then there's JOURNAVX, their non-opioid pain drug, at $50 million in revenue — about 70% sequential growth. The prescription numbers are climbing fast too, roughly 535,000 scripts this quarter. But here's the nuance: gross-to-net is still messy because of a patient support program covering people whose insurance has restrictions like quantity limits.

    ALEX: Management said that normalizes more toward branded-drug norms in the first half of 2027, so investors watching margins on JOURNAVX should expect some lumpiness for a few more quarters.

    JORDAN: On profitability — non-GAAP EPS came in at $4.73, up 5% year-over-year. Gross margin was 85.6%, a slight step down from Q1, which they attributed to product mix as CASGEVY, which costs more to manufacture, becomes a bigger slice of revenue.

    ALEX: And they raised full-year revenue guidance to $13.1 to $13.2 billion, reiterating that $500 million-plus target for non-CF revenue this year.

    JORDAN: Now let's talk about the big strategic move — the Crinetics Pharmaceuticals acquisition. This is roughly an $8.8 billion deal, expected to close in Q3.

    ALEX: This is Vertex adding a fifth commercial pillar — rare endocrine diseases like acromegaly, CAH, and Cushing's syndrome. The two lead assets from Crinetics, paltusotine and atumelnant, are pegged at a combined peak sales opportunity of about $5 billion.

    JORDAN: It's being funded through cash on hand plus a $4.5 billion term loan, and management said it should become accretive to operating income in 2029 — so this is a multi-year bet, not an immediate earnings boost.

    ALEX: Let's talk pipeline, because there's a lot moving. The renal franchise is arguably the most important near-term catalyst — povetacicept, or "Povi," for IgA nephropathy has an FDA decision date of November 30th after a really strong phase III interim analysis.

    JORDAN: And on the call, Reshma Kewalramani, the CEO, made a pretty confident case for Povi's differentiation — she cited a 52% reduction in proteinuria, which she called numerically the best in class, plus once-monthly dosing via a small-volume auto-injector patients can use at home.

    ALEX: There was also a great analyst question about how Vertex sees eGFR data compare against a competitor's recently published numbers. Reshma's answer was essentially: strong proteinuria reduction should translate to GFR stabilization, and Vertex believes Povi's numbers on proteinuria, hematuria, and other biomarkers

    This episode includes AI-generated content.
    続きを読む 一部表示
    7 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません